112 related articles for article (PubMed ID: 8471446)
21. [Advanced breast cancer: an evaluation of the cost of recurrence].
Bercez C; Lebrun T; Bonneterre ME; Selke B; Lenne X; Bonneterre J
Bull Cancer; 1999 Jun; 86(6):585-90. PubMed ID: 10417432
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
23. [Breast Cancer: Value-Based Healthcare, Costs and Financing].
Harfouche A; Silva S; Faria J; Araújo R; Gouveia A; Lacerda M; D'Orey L
Acta Med Port; 2017 Nov; 30(11):762-768. PubMed ID: 29279067
[TBL] [Abstract][Full Text] [Related]
24. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
Sagar B; Lin YS; Castel LD
J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874
[TBL] [Abstract][Full Text] [Related]
25. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P
Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264
[TBL] [Abstract][Full Text] [Related]
26. Management and costs of treating lung cancer patients in a university hospital.
Dedes KJ; Szucs TD; Bodis S; Joerger M; Lowy A; Russi EW; Steinert HC; Weder W; Stahel RA
Pharmacoeconomics; 2004; 22(7):435-44. PubMed ID: 15137882
[TBL] [Abstract][Full Text] [Related]
27. Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
Thomas RJ; Williams M; Glen J; Callam M
Breast Cancer Res Treat; 2009 Sep; 117(2):289-95. PubMed ID: 19122976
[TBL] [Abstract][Full Text] [Related]
28. The cost of breast cancer recurrences.
Hurley SF; Huggins RM; Snyder RD; Bishop JF
Br J Cancer; 1992 Mar; 65(3):449-55. PubMed ID: 1558803
[TBL] [Abstract][Full Text] [Related]
29. A model to compute the medical cost of patients in intensive care.
Chaix C; Durand-Zaleski I; Alberti C; Brun-Buisson C
Pharmacoeconomics; 1999 Jun; 15(6):573-82. PubMed ID: 10538330
[TBL] [Abstract][Full Text] [Related]
30. Neutropenic infections add significant costs to palliative chemotherapy in breast cancer.
Korpela J; Salminen E
Anticancer Res; 2002; 22(2B):1337-40. PubMed ID: 12168947
[TBL] [Abstract][Full Text] [Related]
31. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
[TBL] [Abstract][Full Text] [Related]
32. Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran.
Ansaripour A; Zendehdel K; Tadayon N; Sadeghi F; Uyl-de Groot CA; Redekop WK
PLoS One; 2018; 13(10):e0205079. PubMed ID: 30273393
[TBL] [Abstract][Full Text] [Related]
33. Cost of breast cancer treatment. A 4-year longitudinal study.
Legorreta AP; Brooks RJ; Leibowitz AN; Solin LJ
Arch Intern Med; 1996 Oct; 156(19):2197-201. PubMed ID: 8885818
[TBL] [Abstract][Full Text] [Related]
34. Hospital resources consumed for surgical morbidity: effects of preoperative arginine and omega-3 fatty acid supplementation on costs.
Braga M; Gianotti L; Vignali A; Schmid A; Nespoli L; Di Carlo V
Nutrition; 2005; 21(11-12):1078-86. PubMed ID: 16308130
[TBL] [Abstract][Full Text] [Related]
35. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.
Nuijten M; Meester L; Waibel F; Wait S
Pharmacoeconomics; 1999 Oct; 16(4):379-97. PubMed ID: 10623366
[TBL] [Abstract][Full Text] [Related]
37. Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids. Palliative Care Advisory Committee.
Guest JF; Hart WM; Cookson RF
Pharmacoeconomics; 1998 Sep; 14(3):285-97. PubMed ID: 10186467
[TBL] [Abstract][Full Text] [Related]
38. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.
McGuire A; Irwin DE; Fenn P; Gray A; Anderson P; Lovering A; MacGowan A
Value Health; 2001; 4(5):370-5. PubMed ID: 11705127
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of day and inpatient psychiatric treatment: results of a randomised controlled trial.
Creed F; Mbaya P; Lancashire S; Tomenson B; Williams B; Holme S
BMJ; 1997 May; 314(7091):1381-5. PubMed ID: 9161310
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
